Consistent, defined and scalable human iPSC-derived disease models for ALS and FTD research and drug discovery
Powered by opti-ox
Powered by opti-ox
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) are closely related progressive and fatal neurodegenerative conditions for which there is no cure. One of the biggest challenges slowing down the pace of ALS and FTD drug discovery research is the lack of consistent, physiologically relevant human cell models that accurately represent disease phenotypes and human pathophysiology in vitro.
We have developed ioDisease Model Cells with the aim of solving these challenges.
Researchers can now access ALS and FTD disease-relevant mutations such as SOD1, FUS, MAPT and TDP-43 (TARDBP) genetically engineered in ioGlutamatergic Neurons and ioMotor Neurons.
Our TDP-43 and MAPT disease models show disease-related phenotypes of reduced neuronal activity and hyperphosphorylation respectively, when compared to a genetically matched control. ioDisease Model Cells are defined, consistent, and scalable, supporting translational research for the identification of new therapeutics that could halt or reverse the devastating effects of ALS and FTD.
Discover our ioDisease Model Cells for ALS and FTD research and drug discovery below.
Watch our scientist and cellular phenotyping expert Luke Foulser present his poster on our ioMotor Neurons at the MaxWell Biosystems Summit 2024. Learn about the characterisation of these cells, including their electrophysiological functionality, and their indicated spinal cell identity and clump-free morphology.
This poster presented at AD/PD 2023 shows FTD and ALS disease-related phenotypic data for ioGlutamatergic Neurons disease model cells carrying a mutation in MAPT or TDP-43 (TARDBP).